Core Insights - Resideo Technologies reported record highs in net revenue, Adjusted EBITDA, and adjusted earnings per share for the full year 2025, exceeding the high end of its 2025 outlook ranges [3][4] Financial Performance - For the full year 2025, Resideo achieved net revenue of approximately $7.5 billion, an increase of 11% year-over-year, with Adjusted EBITDA rising 20% to $833 million and adjusted EPS increasing 17% to $2.68 [6] - In Q4 2025, total net revenue was $1.895 billion, up 2% year-over-year, with Adjusted EBITDA increasing 21% to $226 million, although adjusted EPS fell to $0.50 due to higher interest expenses [6][14][15] Segment Performance - The Products and Solutions segment grew organic net revenue by 4% in 2025, driven by demand for safety products and price increases for OEM products, with gross margin expanding by 110 basis points [2] - ADI's organic net revenue increased by 3% for the year, with a gross margin expansion of 200 basis points year-over-year, attributed to a favorable product mix and sales of lower-cost inventory [1][12] Operational Developments - ADI is fully operational on its new ERP system, which has improved customer confidence and service [11] - The integration of Snap One has delivered approximately $75 million in synergies, 18 months ahead of schedule, with further synergies expected [5][21] 2026 Guidance - For 2026, Resideo expects net revenue between $7.8 billion and $7.9 billion, Adjusted EBITDA between $935 million and $985 million, and diluted EPS between $3.00 and $3.20 [5][24] - The company anticipates growth in both segments, with ADI expected to grow faster than Products and Solutions, and a modest total company gross margin expansion [19] Market Outlook - Resideo's 2026 outlook is cautious, with expectations of little growth in the U.S. residential housing market and low single-digit growth in repair and remodel sectors [18]

Q4'25 and FY25 Earnings Presentation February 24, 2026 Disclaimer Forward-Looking Statements This presentation and the related conference call contain "forward-looking statements." All statements, other than statements of fact, that address activities, events or developments that we or our management intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe forward- looking statements are based upon reasonable assumptions, such stateme ...

Core Viewpoint - AnaptysBio plans to separate its business into two publicly traded entities, focusing on biopharma operations and a royalty portfolio, with a target separation date in Q2 2026, although this may be subject to slight delays [4][7]. Biopharma Operations - The new biopharma entity will include three clinical-stage programs: CD122 (ANB033), ANB101, and rosnilimab, and will be capitalized to reach key readouts in the CD122 program [2][5][12]. - AnaptysBio entered 2026 with approximately $310 million in cash, which could fund the biopharma operations into 2028 if allocated appropriately [5][11]. - CD122 is currently in a phase 1b trial for celiac disease, with data expected in Q4 2026, and plans to initiate a phase 1b trial for eosinophilic esophagitis imminently, with results anticipated in 2027 [13][14]. Royalty Portfolio - The royalty-focused entity will be anchored by royalties on GSK's Jemperli, which is projected to have a revenue run rate of approximately $1.5 billion, potentially reaching $1.8 billion this year if growth trends continue [6][7]. - The royalty rate for Jemperli is structured at 8% up to $1 billion in revenues, escalating to 25% at $2.5 billion [9]. - The royalty entity will also include potential economics from Vanda's imsidolimab, which is seeking accelerated approval for generalized pustular psoriasis [10]. Market Dynamics - Faga noted that GSK's Jemperli has gained market share in frontline endometrial cancer due to positive overall survival data, with European approvals lagging behind the U.S. [8]. - GSK has historically guided for peak sales of Jemperli to exceed £2 billion (approximately $2.7 billion), with potential for additional indications and combinations to contribute to revenue [8]. Strategic Considerations - The separation is framed as a dividend of the biopharma operations to existing shareholders, allowing them to retain proportional ownership in both entities post-separation [3][4]. - AnaptysBio is also addressing ongoing litigation related to Jemperli, which is described as a specific contractual matter that does not impact the separation process [10].

Core Viewpoint - Kraft Heinz has decided to pause its previously announced separation plan to focus on returning to profitable growth, with the new CEO emphasizing that many challenges are fixable and within the company's control [1][2] Financial Performance - For the full year, Kraft Heinz reported a net sales decrease of 3.5%, totaling $24.9 billion, while fourth quarter net sales fell by 3.4% to $6.4 billion [1] - The company experienced a significant operating loss of $4.7 billion for the year, primarily due to non-cash impairment losses amounting to $9.3 billion [1] Strategic Initiatives - Kraft Heinz introduced a $600 million investment aimed at accelerating growth in its Taste Elevation portfolio and recovering its U.S. retail business [1] - The decision to pause the separation plan is intended to ensure that all resources are focused on executing the operating plan effectively [1]

Financial Performance - Kraft Heinz's Q3 2025 organic net sales reached $6.2 billion, a decrease of 2.5% compared to the previous year[17] - The company's constant currency adjusted operating income was $1.1 billion, down 17% year-over-year[17] - Adjusted EPS was $0.61, a decrease of 18.7% year-over-year[18] - Year-to-date free cash flow was $2.5 billion, an increase of 23%[18] - Adjusted Gross Profit Margin decreased by 200 basis points to 32.3%[17] Business Segments - North America's organic net sales decreased by 3.8%, with a 0.4 percentage point increase in price offset by a 4.2 percentage point decrease in volume/mix[112] - International organic net sales decreased by 1.4%, with a 1.0 percentage point increase in price offset by a 2.4 percentage point decrease in volume/mix[112] - Emerging Markets organic net sales increased by 4.7%, driven by a 4.0 percentage point increase in price and a 0.7 percentage point increase in volume/mix[112] Investments and Outlook - The company is increasing its investments in marketing, with a target of at least 4.8% of net sales[156] - Kraft Heinz anticipates an adjusted gross profit margin decrease of approximately 100 basis points year-over-year[156] - The company expects interest expense to be approximately $950 million and other expenses to be approximately $250 million[156]

Core Viewpoint - Warner Bros. Discovery is exploring strategic alternatives, including a potential full acquisition or asset sales, following unsolicited interest from third parties, leading to a significant rise in its stock price [1][8]. Group 1: Company Strategy - The company is planning to separate into two distinct entities, one for Warner Bros. and another for Discovery, while also considering other strategic options [3][8]. - Warner Bros. Discovery has received acquisition offers from Paramount Skydance, with interest from Netflix and Comcast in some of its assets [5][8]. Group 2: Financial Performance - Despite a slight revenue growth in the second quarter, the company reported that net income would have been negative without a one-time pre-tax gain on debt extinguishment [4]. - As of the end of the second quarter, Warner Bros. Discovery had $4.9 billion in cash and $35.6 billion in total debt, with a market capitalization of around $50 billion [6]. Group 3: Market Considerations - A full acquisition may be challenging due to the company's significant debt, which could limit the premium over the current stock price [6][8]. - Selling parts of the company could be a more viable option, allowing the company to use proceeds to reduce its debt [7].